Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02122770 · ClinicalTrials.gov registry record · Phase 1
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02122770 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 51 participants.
The verdict
NCT02122770, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose administration of itraconazole on the single-dose IV PK of MLN4924.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Fluconazole
- DRUG Itraconazole
- DRUG MLN4924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-04-01 |
| Est. Completion | 2017-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02122770
The ClinicalTrials.gov registry entry for NCT02122770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02122770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02122770 about?
NCT02122770 is a clinical study titled "Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors". The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose administration of itraconazole on the single-dose IV PK of MLN4924.
What is the current status of trial NCT02122770?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2014-04-01. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT02122770?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Fluconazole (DRUG), Itraconazole (DRUG), MLN4924 (DRUG).
Who is sponsoring clinical trial NCT02122770?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.